Juxtaglomerular cell tumor (JGCT), or reninoma, is a typically benign neoplasm generally affecting adolescents and young adults due to modified smooth muscle cells from the afferent arteriole of the juxtaglomerular apparatus. Patients experience symptoms related to hypertension and hypoka-lemia due to renin-secretion by the tumor. MRI, PET, CT, and renal vein catheterizations can be used to capture JGCTs, with laparoscopic ultrasonography being most cost-efec-tive. Surgical removal is the best option for management; electrolyte imbalances are a potential complication which may be assuaged via pre-surgical administration of aliskiren, a renin inhibitor. Considering the vast etiology for hypertension and rarity of JGCT, the diagnosing physician must have a high index of suspicion for JGCT. Early recognition and management can help prevent cardiovascular or pregnancy complications and fatalities, vascular invasion and metastasis, improve quality of life, and limit socioeconomic liabilities. Herein we review the epidemiology, genetics, histopathol-ogy, clinical presentation, and management of this rare condition. The impact of genetics on prognosis warrant further research.

Juxtaglomerular cell tumor (JGCT), or reninoma, is a rare disease resulting from renin-induced hypertension. Dysfunction in juxtaglomerular cells lead to the over-expression of renin. Although presented with limited cases, diagnosis of JGCT occurs within young adults and adolescents with some occurrences within young children [1,2]. JGCT-induced hypertension is the primary symptom with other rare occurrences such as myocar-dial infarction. JGCT can coexist with various forms of cancer, indirectly enhancing those various types of cancers. In most cases presented within literature, JGCTs are benign tumors in the kidney. Malignant tumors may be expressed in the kidney or liver, however only a handful of cases have shown this result. Herein we review the epidemiology, genetics, histopathology, clinical presentation, and management of this rare condition.

Under normal conditions, the production of the protease renin occurs within juxtaglomerular cells and the functions as the rate-limiting step within the renin-an-giotensin system. Renin is converted to its active form through proteolysis within juxtaglomerular cells and stored within granules. The number of juxtaglomerular cells varies based on age and intensity of stimulation [3]. Renin is rapidly released upon response to a stimulus. Beta-adrenergic receptors are crucial for the rate of renin generation, modulated through cyclic adenosine mono-phosphate, the primary catalyst for renin mRNA [4]. The angiotensin II pathway contributes as a negative feedback regulator indirectly through mediation of macula densa inputs and the baroreceptor [4]. COX-2 and nNOS pathways are other significant regulatory mechanisms of renin through fluctuation of PGE2, nitric oxide and PGI2 [4,5]. As renin granules function deplete, surface area of the cell membrane increases, leading to oversaturation of renin at a quantal rate [3]. Imbalance of renin secretion hinders neurotransmitter pathways, endocrine and para-crine receptors, and disruptions of cells dependent on cyclic AMP pathway [6]. Other components indirectly impacted are cAMP response element-binding protein, a substrate essential for renin gene expression, and the respective activator p300 [7]. Overproduction of renin escalates aldosterone levels, leading to hypertension [2,8]. Mechanical disruption has been associated with JGCT and connexin proteins within the cellular gap junction. Substantial depletion of connexin-40 have been associated with JGCT-induced hypertension within a mice model [6,9,10]. Connexin-45 demonstrates identical effects as connexin-40, to a lesser extent [11].

There are approximately 100 reported cases of JGCT in the literature. Based on the current cases, diagnosis of JGCT is consistent between the ages of adolescent and young adults [2]. It is also twice as common in women as men. Suspicion of JGCT is viable within young hypertensive females [12]. A 60-year-old patient case study revealed the occurrence of a renal producing tumor shortly after a menopausal syndrome diagnosis. Hypertension was diagnosed 6 months prior to the procedure. Tumor was identified as benign and removed with a unilateral adrenalectomy. Diagnosis of hypertension may indicate the reoccurrence of adrenocortical carcinoma [13]. A similar case presented in a 12-year-old female patient experiencing elevated levels of blood renin concentration, aldosterone and high blood pressure. Blood potassium was slightly decreased from normal ranges, as the patient was experiencing extended salt hunger. CT scan revealed 6 cm tumor on her left kidney [14].

Based on a dual case study with a 12-year-old patient and 41-year-old patient, genetic analysis revealed a loss in chromosome 9, 11 and X in both tumors. Although no pathology has been revealed, the specified chromosomal loss may be directly linked to JGCT, as both tumors expressed JGCT phenotypically [14]. The roles of alleles p53 and Rb are significant for renin-gene expression. In an animal study, p53 and Rb alleles were selectively deleted causing elevated levels in glucagon and presence of metastatic tumors [15].

There are several other renin-producing tumors that correlate with JGCT, as listed in Table 1. Development of JGCT as a secondary cause of hypertension can remain undetected and lead to miscarriage if not treated immediately, as shown previously in a case study [16]. Symptoms of desmoplastic small round cell tumor are consistent with that of JGCT. A case study shows a 20-year-old patient experiencing elevated plasma renin levels, aldosterone, and severe hypertension and hypo-kalemia. Desmoplastic small round cell tumor is a malignant tumor and derives from the same mRNA precursor for renin and shares identical metabolic processes as JGCT [17]. A similar case is presented in a 4-year-old male patient diagnosed with Wilms' tumor. The symptoms of hypertension and increased renin expression are consistent in patients diagnosed with Wilms' tumor, a possible correlation with undetected JGCT [18,19].

Deletion of RBP-J, a progenitor within bone marrow which expresses renin, is linked to inducing B-cell leukemia. Under conditions of JGCT, the expression of RB-P-J is hindered, leading to the overexpression of renin, a possibility that JGCT and B-cell leukemia may be correlated [20]. Pro-renin receptors are higher in concentration when plasma renin levels are elevated, a symptom of JGCT. Pro-renin receptors have been associated in cell proliferation within breast cancer cells [21]. Pro-renin receptors were overexpressed in 4 types of breast cancers causing small RNA interference of healthy cells [21]. Cystadenocarcinoma (ovarian cancer) identified in a 46-year-old patient, included hypertension, hypokalemia and elevated plasma renin concentration and aldoster-one (JGCT-identical symptoms). Lab analysis revealed overexpression of renin and abnormalities in juxtaglom-erular cells [22]. Identical symptoms were expressed in renin-producing metastasized adrenocortical carcinoma, with serum staining revealing positively marked antibodies against renin and cytochrome P450 [23]. A few cases studies assessed the relevance of JGCT in uterine leio-myosarcoma. Symptoms in JGCT have been identical to case reports involving uterine leiomyosarcoma [24]. An-giotensin II receptors AT1 and AT2 (disrupted function expressed in JGCT) show dysfunction in human leiomy-osarcoma cells to induce apoptosis [25].

Renin-producing hepatoblastoma is caused by severe hypertension and elevated plasma renin activity induced neurological dysfunction. Such a case is presented in a 22-month-old infant presented with right-side partial seizures. Due to the rarity of the secreting tumor, a clear pathology cannot be established because of insufficient laboratory assays. Assessment of this case was based on slightly elevated concentration of liver enzymes and CT scans revealing the metastasized tumors [26]. Positive results of JGCT was conducted through CD 34 staining with follow-ups on blood pressure and serum potassium levels [12].

History and Physical Examination

Angiotensin receptor blocker medication may disguise the symptoms of JGCT based on a delayed diagnosis of a 33-year-old woman undergoing pregnancy. A tumor was located on the right kidney after the patient suspended the administration of the angiotensin receptor blocker due to pregnancy. The tumor identified as benign was removed by a right partial nephrectomy and invasive procedure [27]. Another case study involving a 24-year-old male patient showed a polymorphism of the ACE gene. The patient underwent thyroidectomy with lymph-adenectomy at the age of 20 according to previous medical record. Abnormal decrease of urinary catecholamines and metanephrines were reported with a MRI screening of a lesion on the right kidney confirming diagnosis of JGCT and pheochromocytoma.

Laboratory Studies

Severe hypokalemia and hyperaldosteronism have been reported before diagnosis of JGCT. Increased levels of kaliuresis, plasma renin, pro-renin, and aldosterone according to bioassays are indications for the possibility of JGCT, as shown within the case study of a 22-year-old male patient [28]. Urinalysis showed hypokalemia and hypochloremia in a case study with 4 patients. Twenty four hour monitoring revealed elevated potassium levels and no significant changes in urea and creatinine [29]. Common symptoms include headache, nocturia, myalgia, and polyuria with the average blood pressure of 201/130 mmHg over a mean duration of 47 months [29].

Genetic Studies

Genetic tests revealed a RET mutation of codon 918, however the epidemiology is yet to be determined [30]. Diagnosis of a 10-year-old boy with cerebral hemorrhages caused by hypertension and JGCT is a rare manifestation of JGCT within children. Hypertension led to reoccurring headaches and neurological deficient symptoms [31]. JGCT induced myocardial infarction in a 28-year-old female was presented as a rare case. Im-mune-histochemical signaling revealed positive results for CD34 but negative for HMB-45, cytokeratin, and ac-tin [32].


Laparoscopic ultrasonography is an effective method to locate renin tumors. Location, blood supply, size, and boundaries of the renal tumors are defined with accuracy, as presented within the diagnosis of 19 clinical cases [33]. MRI and ultrasound scanning assists in locating the size and setting of the tumor [32,34,35]. Bioassays of plasma renin activity, aldosterone, and hypertension assist in determining the severity or presence of tumor. Immunohistochemical markers do not follow a particular pattern unlike microscopic and contrast scanning [36]. Renal artery Doppler ultrasound and DTPA scan can be administered to rule out renal artery stenosis [12]. CT scans and renal vein renin ratios assist in locating the tumor before performing nephrectomy [12]. Renal vein sampling and cross-sectional imaging are increasing in use to diagnose for JGCT within the last decade [37]. Precise location and dimensions of tumors are often located with CT scans of the abdomen [38,39]. Florescent markers are implicated in order to track the progression of metastatic tumors [15]. Further identification of renal lesions can involve selective renal venous catheteriza-tion with an administration of ACE inhibitor prior to a nephrectomy [40].

Presentation of Malignant Reninoma

Most reported cases of JGCT are benign neoplasms, with very few reports of metastasized tumors. JGCTs located within a 46-year-old man were found identical in masses located in the lungs and kidneys. A 15-cm tumor from the right kidney was removed 6 years prior to the formations of the bilateral lung masses. After microscopic examination, masses from the kidney and lung had identical attributes such as abundant delicate vascu-lature intermingled with uniform solid sheets of polygonal cells [41]. Severe hypertension caused by JGCT in an 18-year-old lead to congestive heart failure. Presentation of cardiomyopathy was found significant due to the patients lack of hypertension in medical history, and elevated levels of plasma renin and high blood pressure were associated with the diagnosis of malignant hypertension from JGCT [42]. After an unsuccessful nephrec-tomy in a young female patient, an aggressive mass induced severe hypertension and ACE inhibitors masked hypokalemia pre-surgery [43].

Surgical Resection

During the resection of a JGCT, general anesthesia is administered for percutaneous CT-guided radiofre-quency. Patients may experience dizziness and nausea post-surgery and be diagnosed with hypotension. In a case, hypotension was experienced after the surgical procedure, but later corrected with a saline infusion of 30 minutes [44]. Blood sample is drawn to determine whether hypokalemia persists, along with elevated concentration of plasma renin and aldosterone. With a positive result, the diagnosis is carried further with contrast CT scan or MRI to locate the tumor [1,45].

Partial nephrectomy through an incision is an effective and common approach for removing JGCT-associated tumors [34]. Few situations involved other procedures such as laparoscopic nephron-sparing surgery, as shown within a case of JGCT in a 14-year-old patient with lesions to the right kidney [46]. Time periods ranging from 4-5 days to 1 month after the surgery require blood sample follow-ups to monitor for reoccurring symptoms [34,46,47]. Other post-surgery assessment includes CT scan and glomerular filtration rate in the affected kidney, ranging 6-20 month follow-ups [47].


Oral treatment with aliskiren, a renin inhibitor, has shown promising effects to patients with JGCT, however prolonged use decreases efficacy and may induce reactive renin release [48]. Failure to lower plasma renin activity and blood pressure are associated with prolonged use of aliskiren [49]. However, during a 2-month treatment period pre-surgery described in a case report, blood pressure was normalized and serum potassium levels increased with a 300 mg aliskiren oral treatment. Aliskiren can be beneficial to ease symptoms before a surgical procedure [50].

Although presented with few cases pertaining to JGCT, hypertension remains a persistent condition in adolescents and young adults. Misdiagnosis can lead to undetected JGCT and indirectly impact other malfunctioned systems such as the renin-angiotensin system and juxtaglomerular cell apparatus. Although most cases are presented with benign tumors on the kidney and removed through a nephrectomy, coexistence is possible with other forms of cancers such as B-cell leukemia and breast cancer. Mediation in JGCT can provide mediation in these other forms of cancer, such as regulating the overexpression of renin. Research into the pathological systems involving JGCT should be further encouraged.

The authors are thankful to Drs. Todd Miller, Kelly Warren, Inefta Reid, and Peter Brink for departmental support, as well as Mrs. Wendy Isser and Ms. Grace Garey for literature retrieval.

Trnka P, Orellana L, Walsh M, Pool L, Borzi P: Reninoma: an uncommon cause of renin-mediated hypertension. Front Pediatr 2014; 2:89.
Flynn J: The changing face of pediatric hypertension in the era of the childhood obesity epidemic. Pediatr Nephrol 2013;28:1059- 1066.
Friis UG, Madsen K, Stubbe J, Hansen PB, Svenningsen P, Bie P, Skøtt O, Jensen BL: Regulation of renin secretion by renal jux-taglomerular cells. Pflugers Arch 2013;465: 25-37.
Schnermann J, Briggs JP: Synthesis and secretion of renin in mice with induced genetic mutations. Kidney Int 2012;81:529-538.
Gomez RA: Fate of renin cells during development and disease. Hypertension 2017;69: 387-395.
Wagner C, Kurtz A: Distribution and functional relevance of connexins in renin-pro-ducing cells. Pflugers Arch 2013;465:71-77.
Li P, Zhang J, Zhu Y, Liu M, Xuan J: Regulation of cyclic adenosine monophosphate response element binding protein on renin expression in kidney via complex cyclic adenosine monophosphate response element-binding-protein-binding protein/P300 recruitment. Iran J Kidney Dis 2015;9:440-448.
Martini AG, Xa LK, Lacombe MJ, Blan-chet-Cohen A, Mercure C, Haibe-Kains B, Friesema ECH, van den Meiracker AH, Gross KW, Azizi M, Corvol P, Nguyen G, Reudel-huber TL, Danser AHJ: Transcriptome analysis of human reninomas as an approach to understanding juxtaglomerular cell biology. Hypertension 2017;69:1145-1155.
Hanner F, von Maltzahn J, Maxeiner S, Toma I, Sipos A, Krüger O, Willecke K, Peti-Peterdi J: Connexin45 is expressed in the juxtaglomerular apparatus and is involved in the regulation of renin secretion and blood pressure. Am J Physiol Regul Integr Comp Physiol 2008;295:R371-380.
Gomez RA, Sequeira Lopez ML: Who and where is the renal baroreceptor?: the con-nexin hypothesis. Kidney Int 2009;75:460-462.
Kurtz L, Janssen-Bienhold U, Kurtz A, Wagner C: Connexin expression in renin-produc-ing cells. J Am Soc Nephrol 2009;20:506- 512.
Wolley M, Gordon RD, Stowasser M: Ren-inoma: the importance of renal vein renin ratios for lateralisation and diagnosis. Am J Nephrol 2014;39:16-19.
Wen MJ, Lin YF, Chen JS: Newly developed hypertension as an early marker of recurrence of adrenocortical carcinoma with high renin expression. Int J Urol 2008;15:540-542.
Brandal P, Busund LT, Heim S: Chromosome abnormalities in juxtaglomerular cell tumors. Cancer 2005;104:504-510.
Glenn ST, Jones CA, Sexton S, LeVea CM, Caraker SM, Hajduczok G, Gross KW: Conditional deletion of p53 and Rb in the ren-in-expressing compartment of the pancreas leads to a highly penetrant metastatic pancreatic neuroendocrine carcinoma. Oncogene 2014;33:5706-5715.
Lachvac L, Svajdler M, Valansky L, Nagy V, Benicky M, Frohlichova L, Nyitrayova O: Juxtaglomerular cell tumor, causing fetal demise. Int Urol Nephrol 2011;43:365-370.
Lee HJ, Hyun JS, Jang HS, Sul H, Park SG: Paraneoplastic secondary hypertension due to a renin-secreting desmoplastic small round cell tumor: a case report. Oncol Lett 2014;8: 1986-1992.
Kaverina NV, Eng DG, Largent AD, Daehn I, Chang A, Gross KW, Pippin JW, Hohenstein P, Shankland SJ: WT1 is necessary for the proliferation and migration of cells of renin lineage following kidney podocyte depletion. Stem Cell Reports 2017;9:1152-1166.
Spahr J, Demers LM, Shochat SJ: Renin producing Wilms' tumor. J Pediatr Surg 1981;16: 32-34.
Belyea BC, Xu F, Pentz ES, Medrano S, Li M, Hu Y, Turner S, Legallo R, Jones CA, Tario JD, Liang P, Gross KW, Sequei-ra-Lopez ML, Gomez RA: Identification of renin progenitors in the mouse bone marrow that give rise to B-cell leukaemia. Nat Com-mun 2014;5:3273.
Ohba K, Suzuki T, Nishiyama H, Kaneko K, Hirose T, Totsune K, Sasano H, Takahashi K: Expression of (pro)renin receptor in breast cancers and its effect on cancercell proliferation. Biomed Res 2014;35:117-126.
Iwamoto H, Hirata S, Honda T, Fukasawa H, Kimura N, Hoshi K: Renin-producing serous cystoadenocarcinoma of the ovary: a case report. Eur J Gynaecol Oncol 2002;23:183-186.
Yamanaka K, Iitaka M, Inaba M, Morita T, Sasano H, Katayama S: A case of renin-pro-ducing adrenocortical cancer. Endocr J 2000; 47:119-125.
Moody AM, Ahmed A, Chakrabarty A, Fisher C: Renin-producing leiomyosarcoma originating in the uterus. Clin Oncol (R Coll Radiol) 1995;7:52-53.
Lutzen U, Zhao Y, Lucht K, Zuhayra M, Hedderich J, Cascorbi I, Culman J: Activation of the cell membrane angiotensin AT2 receptors in human leiomyosarcoma cells induces differentiation and apoptosis by a PPARgamma - dependent mechanism. Neo-plasma 2017;64:395-405.
Tavasoli A, Mehrazma M, Hooman N, Afshar Khas L: Severe hypertension and encephal-opathy due to renin-producing hepatoblas-toma. Iran J Cancer Prev 2013;6:227-230.
Kim MJ, Kim JH, Kim IY, Lee DW, Lee SB: Reninoma masked by the use of an angi-otensin receptor blocker. Iran J Kidney Dis 2016;10:413-415.
Leogite J, Schillo F, Viennet G, Wolf JP, De-biere F, Bonneville JF, Zimmermann C, Nar-boni G, Penfornis A: Reninoma: a rare but curable cause of high blood pressure, a case report. Ann Endocrinol (Paris) 2003;64:198-201.
Gu WJ, Zhang LX, Jin N, Ba JM, Dong J, Wang DJ, Li J, Wang XL, Yang GQ, Lu ZH, Dou JT, Lu JM, Mu YM: Rare and curable renin-mediated hypertension: a series of six cases and a literature review. J Pediatr Endo-crinol Metab 2016:29:209-216.
Paragliola RM, Capoluongo E, Torino F, Minucci A, Canu G, Prete A, Pontecorvi A, Corsello SM: A rare case of juvenile hypertension: coexistence of type 2 multiple endocrine neoplasia -related bilateral pheochro-mocytoma and reninoma in a young patient with ACE gene polymorphism. BMC Endocr Disord 2015;15:30.
Mao J, Wang Z, Wu X, Dai W, Tong A: Recurrent hypertensive cerebral hemorrhages in a boy caused by a reninoma: rare manifestations and distinctive electron microscopy findings. J Clin Hypertens (Greenwich) 2012;14:802-805.
Schulze zur Wiesch C, Sauer N, Aberle J: Hypertension and hypokalemia - a reninoma as the cause of suspected liquorice-induced arterial hypertension. Dtsch Med Wochen-schr 2011;136:882-884.
Dong D, Ji Z, Li H, Yan W, Zhang Y: Laparo-scopic nephron sparing surgery assisted with laparoscopic ultrasonography on centrally located renal tumor - single center experience. Urol Int 2016;97:195-199.
Miyano G, Nagano C, Morita K, Yamoto M, Kaneshiro M, Miyake H, Nouso H, Ki-tayama H, Wada N, Fukumoto K, Koyama M, Urushihara N: A case of juxtaglomerular cell tumor, or reninoma, of the kidney treated by retroperitoneoscopy-assisted nephron-spar-ing partial nephrectomy through a small pararectal incision. J Laparoendosc Adv Surg Tech A 2016;26:235-238.
Wu HH, Wang GY, Ma XW, Guo XH: A clinical analysis of reninoma-induced hypertensive crisis associated with reversible posterior encephalopathy syndrome. Zhonghua Nei Ke Za Zhi 2012;51:24-27.
Torricelli FC, Marchini GS, Colombo JR Jr, Coelho RF, Nahas WC, Srougi M: Ne-phron-sparing surgery for treatment of ren-inoma: a rare renin secreting tumor causing secondary hypertension. Int Braz J Urol 2015;41:172-176.
Karaosmanoglu AD, Onur MR, Shirkhoda A, Ozmen M, Hahn PF: Unusual benign solid neoplasms of the kidney: cross-sectional imaging findings. Diagn Interv Radiol 2015; 21:376-381.
Leemingsawat C, Thongtang N: Malignant hypertension due to a large reninoma: a case report. J Med Assoc Thai 2012;95(Suppl 2):S251-255.
Wen J, Li HZ, Ji ZG, Shi BB, Yan WG: Evaluation of retroperitoneoscopic partial nephrectomy with in situ hypothermic per-fusion. Clin Transl Oncol 2012;14:382-385.
Wong L, Hsu TH, Perlroth MG, Hofmann LV, Haynes CM, Katznelson L: Reninoma: case report and literature review. J Hypertens 2008;26:368-373.
Duan X, Bruneval P, Hammadeh R, Fresco R, Eble JN, Clark JI, Vigneswaran WT, Flanigan RC, Picken MM: Metastatic juxtaglomerular cell tumor in a 52-year-old man. Am J Surg Pathol 2004;28:1098-1102.
Cho MJ, Sung EY, Park JA, Lee HD: Congestive heart failure as an initial manifestation of reninoma. J Pediatr Endocrinol Metab 2011; 24:1085-1087.
Venkateswaran R, Hamide A, Dorairajan LN, Basu D: Reninoma: a rare cause of curable hypertension. BMJ Case Rep 2013;2013.
Gil NS, Han JY, Ok SH, Shin IW, Lee HK, Chung YK, Sohn JT: Anesthetic management for percutaneous computed tomography-guided radiofrequency ablation of ren-inoma: a case report. Korean J Anesthesiol 2015;68:78-82.
Oei L, van den Meiracker AH, Oei EH, Moelker A, van Leenders GJ, Rikken B, Ver-hagen P, Clahsen-van Groningen MC, van der Wiel HE: Reninoma: a rare cause of curable hypertension and hypokalemia. Am J Med 2016;129:e131-132.
Pacilli M, O'Brien M, Heloury Y: Laparo-scopic nephro-sparing surgery of juxtaglo-merular cell tumor in a child. J Pediatr Urol 2016;12:321-322.
Wang B, Gong H, Ma X, Li H, Yan Y, Cai W, Shi L, Li X, Zhang X: Retroperitoneal lap-aroscopic nephrotomy along the Brodel line and tumor enucleation for complete intrapar-enchymal renal tumors: a single institution experience. J Endourol 2017;31:1044-1048.
Chao CT, Wu VC: Aliskiren for reninoma. Nephrology (Carlton) 2012;17:308-309.
Sealey JE, Laragh JH: Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises. Am J Hypertens 2009;22:112-121.
Rosei CA, Giacomelli L, Salvetti M, Paini A, Corbellini C, Tiberio G, Muiesan ML: Advantages of renin inhibition in a patient with reninoma. Int J Cardiol 2015;187:240-242.
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.